Keyword: Seres Therapeutics
Chimerix’s CEO replaced by a trio of officers; Decibel hires new CMO; and Kiadis poaches Ablynx’s CSO.
Seres Therapeutics cut about 30% of its workforce and said goodbye to its chief scientific officer as it narrows its clinical efforts.
CMO Sean Bohen and I-O head David Berman are leaving AstraZeneca, while Roche's Omar Khwaja and Pearl Huang land at new biotechs.
Seres Therapeutics is promoting its chief operating and financial officer, Eric Shaff, to succeed Roger Pomerantz as its new president and CEO.
Celgene brings on Keytruda R&D exec Alise Reicin in shake-up; IBM Watson Health chief Deborah DiSanzo steps down; and AbbVie CFO Bill Chase to retire.
The appointment puts Horgan in charge of a pipeline of drugs designed to treat disease through the alteration of the microbiome.
The Parker Institute for Cancer Immunotherapy is sponsoring the trial, which will take place at the MD Anderson Cancer Center.
The combined company starts life with Crestovo’s phase 2 Clostridium difficile candidate and a large-scale stool donation program.
Microbiome startup AOBiome Therapeutics has seen positive data from its phase 2b trial in acne.
The microbiome pioneer thinks the data support the rapid advance of SER-287 deeper into the clinic, although question marks about the results remain.